People | September 20, 2024
Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
This license will enable Abbott to enhance access to this novel therapy to more patients across India
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Subscribe To Our Newsletter & Stay Updated
